NCT00348790 2018-10-26
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Northwestern University
Phase 2 Completed
Clinical Trials
11 trialsNCT00052013 2017-03-06
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Novartis
Phase 2 Completed
NCT00072475 2016-08-01
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00053885 2016-07-01
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00134355 2015-01-19
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00160043 2014-12-16
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.
Bayer
Phase 2 Completed
NCT00563823 2013-08-02
Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00226005 2012-05-09
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer Research Team
Phase 2 Completed
NCT00590343 2011-06-29
PTK787
Louisiana State University Health Sciences Center in New Orleans
Phase 2 Completed
NCT00117299 2010-05-27
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
University of Helsinki
Phase 2 Completed
NCT00165347 2007-12-21
Protein Tyrosine Kinases (PTK) in Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed